1. Оганов Р.Г. Концепция факторов риска как основа профилактики сердечно-сосудистых заболеваний. Врач 2001;(7):3-6
2. Оганов Р.Г., Мамедов М.Н., редакторы. Школа по диагностике и лечению метаболического синдрома. Пособие для врачей. М.: Медицинская книга; 2007.
3. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26(11): 3160-7
4. Bartnik M, Ryden L, Ferrari R, et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004; 25(21):1880-90.
5. Мамедов М.Н. Опыт комбинированной антигипертензивной терапии у больных с метаболическим синдромом. Росс кардиол журн 2006;(4):69-74
6. Padwal R, Majumdar SR, Johnson JA, et al. A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care 2005;28(3):736-44.
7. Nilsson P., Cifkova R., Kjeldsen S. Mancia G. Prevention of the 2 diabetes mellitus. J Hypertens 2006;24(12):2478-82.
8. Williams B. Recent hypertension trials. Implications and controversies. J Am Coll Cardiol 2005;45(6):813-27.
9. Valensi P. All in one. Monde Moderne (France) 2004: 71-110, 184- 209.
10. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-convertingenzyme inhibitor, ramipil, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342(3):145-53.
11. Lonn E, Yusuf S, Dzavik V, et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001; 103(7):919-25.
12. Kaplan NM. The CARE Study: a postmarketing evaluation of ramipril in 11,100 patients. The Clinical Altace Real-World Efficacy (CARE) Investigators. Clin Ther 1996; 18(4): 658-670
13. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355(9200):253-9
14. Marre M, Lievre M, Chatellier G, et al; DIABHYCAR Study Investigators. Effects of low dose ramipril on the cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomized, double blind, placebo controlled trial (The DLABHYCAR study). BMJ 2004;328:495.
15. Ingelfinger JR, Solomon CG. Angiotensin-converting-enzyme inhibitors for impaired glucose tolerance--is there still hope? N Engl J Med 2006;355(15):1608-10
16. The DREAM trial investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355(15):1551-62
17. The DECODE study group. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. Diabetologia 1999; 42: 647-54
18. Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program research group. Reduction in the incidence of the type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346(6):393-403
19. Tuomilehto J, Lindström J, Eriksson JG, et al.; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344(18):1343-50
